Journey Medical to acquire the molecule stabilizing technology of VYNE Therapeutics for $475m.

Journey Medical, a pharmaceutical company, agreed to acquire the molecule stabilizing technology of VYNE Therapeutics, a pharmaceutical company, for $475m. “This transaction is a key component of our strategy to focus our future efforts and resources on the development of our immuno-inflammatory pipeline assets. We believe that Journey’s growing dermatology portfolio and extensive commercial expertise provide significant opportunity for the topical minocycline franchise moving forward," David Domzalski, VYNE CEO.